RTM receives marketing authorisation for Fludeoxyglucose (18F)

We are happy to announce that RTM has received marketing authorization for 18F-FDG of 17 July 2018.

Fludeoxyglucose (18F) RTM 200 MBq/ml, solution for injection will become commercially available in The Netherlands in October, with roll-out to Belgium and Germany planned in 2019.

RTM receives marketing authorisation for Fludeoxyglucose (18F)

Other news

Cooperation RTM-Alliance Medical

Cooperation RTM-Alliance Medical

It is with great pleasure that we announce our cooperation with Alliance Medical Group (AMG) regardi...

Read more

LinkedIn post ESRR2024

LinkedIn post ESRR2024

📢 Important update on EU #GMP Annex 1 at #ESRR2024!  The revised EU GMP Annex 1, effecti...

Read more

GMP-certificate received

GMP-certificate received

Today we received our GMP-certificate!The results of the inspection were excellent and no shortcomin...

Read more

Production of novel diagnostic radionuclides in small medical cyclotrons

Production of novel diagnostic radionuclides in small medical cyclotrons

Employees from RTM and Radboudumc have published a new article: 'Production of novel diagnostic radi...

Read more

Interested in a collaboration?

Contact us to discuss the possibilities.